Skip to main content
SpringerLink
Log in

Antivirale Therapie der Zukunft: Was ist in der Pipeline?

HIV-Therapie

Future prospects of antiviral HIV therapy: what is in the pipeline?

  • FORTBILDUNG -- ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Die meisten Menschen mit HIV-Infektion können derzeit gut behandelt werden, oftmals mit nur einer Tablette täglich, bestehend aus zwei oder drei antiviralen Wirkstoffen. Dank kontinuierlicher Forschung macht der Fortschritt nicht Halt. Zu den neuen Entwicklungen der antiretroviralen Therapie zählen sowohl Substanzen mit neuen Wirkmechanismen als auch langwirksame Medikamente mit neuen Applikationsformen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Markowitz M, Grobler JA. Islatravir for the treatment and prevention of infection with the human immunodefciency virus. Curr Opin HIV AIDS 2020;15:27–32

    Article  CAS  Google Scholar 

  2. Durham PG, Gatto G, Johnson L, Marzinke MA, Swarner S, Rothrock G, et al. In vitro and in vivo evaluation of biodegradable implant containing TAF for HIV PrEP. 24th CROI, Seattle, WA, USA, 13-16 Feb. 2017; Abstract 420

  3. Chua CYX, Jain P, Ballerini A, Bruno G, et al. Transcutaneously refllable nanofuidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. J Control Release 2018;286:315–325

    Article  CAS  Google Scholar 

  4. Coelho L, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Preexposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV 2019;6:e788–e799

    Article  Google Scholar 

  5. Benhabbour SR, Kovarova M, Jones C, Copeland DJ, Shrivastava R, Swanson MD, et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat Commun. 2019;10(1):4324

    Article  Google Scholar 

  6. Zhou T, Su H, Dash P, Lin Z, Dyavar Shetty BL, Kocher T, Szlachetka A, Lamberty B, Fox HS, Poluektova L, Gorantla S, McMillan J, Gautam N, Mosley RL, Alnouti Y, Edagwa B, Gendelman HE. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profles. Biomaterials 2018;151:53–65

    Article  CAS  Google Scholar 

  7. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, noninferiority trial. Lancet 2017;390(10101):1499–1510

    Article  CAS  Google Scholar 

  8. Overton ET, Orkin C, Swindells S, Arasteh K, GórgolasHernández-Mora M, Pokrovsky V, et al. Long-acting cabotegravir and rilpivirine is noninferior to oral ART as maintenance therapy for HIV-1 infection: Week 48 pooled analysis from the phase 3 ATLAS and FLAIR studies. 10th IAS Conference on HIV Science, Mexico City, Mexico, 21-24 July 2019; Abstract MOPEB257

  9. Markowitz M, Sarafanos SG. 4’-Ethynyl-2-fuoro-2’-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS 2018;13(4):294–299

    Article  CAS  Google Scholar 

  10. Molina JM, Yazdanpanah Y, Saud A, Bettacchi C, Anania C, DeJesus E, et al. MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine establishes and maintains viral suppression through 48 weeks in treatment-naïve adults with HIV1 infection. 10th IAS Conference on HIV Science, Mexico City, 21-24 July 2019; Abstract WEAB0402LB

  11. Begley R, Rhee MS, West SK, Ling J, Escobar J, Mathias A. Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor. 17th European AIDS Conference (EACS), Basel, Switzerland, 6–9 Nov. 2019; Abstract PS13/1

  12. Daar ES, McDonald C, Crofoot G, Ruane P, Sinclair G, Patel H, et al. Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efcacious in people living with HIV. 17th European AIDS Conference (EACS), Basel, Switzerland, 6–9 Nov. 2019; Abstract PE3/17

  13. Lataillade M, Lalezari J, Aberg J, Molina J-M, Kozal M, Cahn P, et al. Week 96 safety and efcacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study). 10th IAS Conference on HIV Science, Mexico City, July 21-24, 2019; Abstract MOAB0102

  14. Ackerman P, Gartland M, Chabria S, Mannino F, Garside L, Kustra1 R, et al. Baseline and emergent genotypic and phenotypic results in HIV-1-infected, heavily treatment-experienced (HTE) participants meeting protocol-defned virologic failure (PDVF) criteria through week 96 in the fostemsavir (FTR) phase 3 BRIGHTE study. 17th European AIDS Conference (EACS), Basel, Switzerland, 6-9 Nov. 2019; Poster PE17/6

  15. Alessandri-Gradt E, Charpentier C, Leoz M, Mourez T, Descamps D, Plantier JC. Impact of natural polymorphisms of HIV-1 nongroup M on genotypic susceptibility to the attachment inhibitor fostemsavir. J Antimicrob Chemother 2018;73(10):2716–2720.

    Article  CAS  Google Scholar 

  16. Cambou MC, Landovitz RJ. Novel Antiretroviral Agents. Curr HIV/AIDS Rep. 2020;17(2):118–124; Review

    Article  Google Scholar 

  17. Wensel D, Sun Y, Davis J, Li Z, Zhang S, McDonagh T, Langley D, et al. GSK3732394: a multi-specifc inhibitor of HIV entry. J Virol. 2019;93(20)

    Google Scholar 

  18. Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials 2018; 19(3):85–93

    Article  CAS  Google Scholar 

  19. Dhody K, Kazempour K, Pourhassan N, Maddon PJ. Final results of the pivotal study of PRO 140 SC in heavily treatment-experienced HIV patients. American Society for Microbiology (ASM) Microbe, San Francisco, CA, 20-24 June 2019; Poster AAR-713

  20. Liu Y, Cao W, Sun M, Li T. Broadly neutralizing antibodies for HIV-1: efcacies, challenges and opportunities. Emerg Microbes Infect. 2020;9(1):194–206

    Article  CAS  Google Scholar 

  21. Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 2018;561:479–484

    Article  CAS  Google Scholar 

  22. Joshi S, Fernando D, McKenzie L, et al. The initial phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs, Noordwijk, Netherlands, 14-16 May 2019; Abstract 4

  23. DeJesus E, Harward S, Jewell RC, JohnsonM, Dumont E,Wilches V, Halliday F, Talarico C, Jefrey J, Gan K, Felizarta FB, Scribner A, Rampogal M, Benson P, Johns BA. A phase IIa study of novel maturation inhibitor GSK2838232 in HIV patients. 26th CROI, Seattle, Washington, 4-7 March 2019; Abstract 142

  24. Vansant G, Vranckx LS, Zurnic I, Van Looveren D, Van de Velde P, Nobles C, et al. Impact of LEDGIN treatment during virus production on residual HIV-1 transcription. Retrovirology 2019;16(1):8

    Article  Google Scholar 

  25. Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 2018;563(7731):360–364

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MUC Research GmbH, Karlsplatz 8, D-80335, München, Deutschland

    Eva Wolf MPH

  2. MVZ Karlsplatz, Karlsplatz 8, D-80335, München, Deutschland

    Sebastian Noe

Authors
  1. Eva Wolf MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastian Noe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva Wolf MPH.

Additional information

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wolf, E., Noe, S. Antivirale Therapie der Zukunft: Was ist in der Pipeline?. MMW - Fortschritte der Medizin 162 (Suppl 2), 50–54 (2020). https://doi.org/10.1007/s15006-020-0647-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-020-0647-9

Keywords

Search

Navigation